Oral iron chelation with deferiprone

Pediatric Clinics of North America

Volumn 44, Issue 1, 1997, Pages 235-247

  Diav Citrin, O ^a   Koren, G ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN;

AGRANULOCYTOSIS; ARTHROPATHY; HUMAN; IRON CHELATION; IRON THERAPY; ORAL DRUG ADMINISTRATION; REFRACTORY ANEMIA; REVIEW; THALASSEMIA MAJOR;

EID: 0031058489     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-3955(05)70471-5     Document Type: Article

References (76)

1. 1) Indian J Pediatr 60 1993 509 516
2. 1 therapy in iron-loaded thalassemics is a rare and reversible event. Abstract of the Fourth International Conference on Oral Chelation, Bombay, India, 1993, p 62.
3. 1, an oral iron chelator in transfusion-dependent thalassemia: Indian trial Br J Haematol 82 1992 460 466
4. 1-oral iron chelator in transfusion-dependent thalassemics over the last three years. Abstract of the Fifth International Conference on Thalassemias and Haemoglobinopathies, Nicosia, Crete, 1993, p 192.
5. 1 Lancet 335 1990 601
6. 1) therapy: A report by the International Study Group on Oral Iron Chelators Br J Haematol 91 1995 224 229
7. 1 experience Bailliere's Clin Haematol 7 1994 941 961
8. F.N. Al-Refaie A.V. Hoffbrand Oral iron chelation therapy Recent Advances in Haematology 7 1993 185 216
9. 1) in patients with iron overload Br J Haematol 89 1995 403 408
10. 1 Br J Haematol 82 1992 431 436
11. F.N. Al-Refaie S. Wilkes P.A. Veys Agranulocytosis in a patient with thalassemia major during treatment with oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one Acta Haematol 89 1993 86 90
12. 1) and desferrioxamine on myelopoiesis using a liquid culture system Br J Haematol 87 1994 196 198
13. F.N. Al-Refaie B. Wonke A.V. Hoffbrand Deferiprone-associated myelotoxicity Eur J Haematol 53 1994 298 301
14. 1) in thalassemia major Blood 80 1992 593 599
15. F.N. Al-Refaie B. Wonke D.G. Wickens Zinc concentration in patients with iron overload receiving oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine J Clin Pathol 47 1994 657 660
16. American Academy of Pediatrics, Committee on Nutrition Zinc Pediatrics 62 1978 408 412
17. M. Barry D.M. Flynn E.A. Letsky Long-term chelation therapy in thalassemia major: Effect on liver iron concentration, liver histology, and clinical progress BMJ 2 1974 16 20
18. 1). II. Clinical observations Br J Haematol 76 1990 301 304
19. A. Bel E. Martinod P. Menasche Cardioprotective effect of desferrioxamine Acta Haematol 95 1996 63 65
20. M. Berkovitch R.M. Laxer R. Inman Arthropathy in thalassemia patients receiving deferiprone Lancet 343 1994 1471 1472
21. M. Berkovitch D. Matsui S.H. Lamm Recent increases in numbers and risk of fatalities in young children ingesting iron preparations Vet Hum Toxicol 36 1994 53 55
22. G.M. Brittenham A.R. Cohen C.E. McLaren Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major Am J Haematol 42 1993 81 85
23. G.M. Brittenham P.M. Griffith A.W. Nienhuis Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major N Engl J Med 331 1994 567 573
24. 1) in iron-loaded patients with sickle cell disease Blood 83 1994 2329 2333
25. J.M. Cunningham F.N. Al-Refaie A. Hunter Differential toxicity of α-ketohydroxypyridine iron chelators and desferrioxamine to human hemopoietic precursors in vitro Eur J Haematol 52 1994 176 179
26. A. Donfrancesco G. Deb L. DeSio Role of deferoxamine in tumor therapy Acta Haematol 95 1996 66 69
27. M.A. Engle M. Erlandson C.H. Smith Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis Circulation 30 1964 698 705
28. R.W. Evans M. Sharma W. Ogwang The effect of α-ketohydroxypyridine chelators on transferrin saturation in vitro and in vivo Drugs of Today 28 suppl 1992 19 23
29. F.F. Fassos M. Berkovitch N. Daneman Efficacy of deferiprone in the treatment of acute iron intoxication in rats Clin Toxicol 34 1996 279 287
30. 1 Drugs of Today 28 suppl 1992 133 135
31. J.M.C. Gutteridge D.A. Rowley E. Griffiths Low-molecular weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis Clin Sci 68 1985 463 467
32. B. Halliwell J.M.C. Gutteridge Oxygen, free radicals, and iron in relation to biology and medicine: Some problems and concepts Arch Biochem Biophys 246 1986 501 514
33. C. Hershko A. Pinson G. Link Prevention of anthracycline cardiotoxicity by iron chelation Acta Haematol 95 1996 87 92
34. Hider RC, Kontoghiorghes GJ, Silver J. UK Patent: GB-2118176, 1982.
35. D. Hileti P. Panayiotidis A.V. Hoffbrand Iron chelators induce apoptosis in proliferating cells Br J Haematol 89 1995 181 187
36. A.V. Hoffbrand Oral iron chelation Semin Hematol 33 1996 1 8
37. A.V. Hoffbrand A.N. Bartlett P.A. Veys Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial Lancet 2 1989 457
38. M.A.M. Hussain D.M. Flynn N. Green Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload Lancet 1 1976 977 979
39. 1 for oral iron chelation Drugs of Today 28 suppl 1992 143 147
40. H. Keberle The biochemistry of desferrioxamine and its relation to iron metabolism Ann N Y Acad Sci 119 1964 758 768
41. 1 (3-hydroxy-1,2-dimethyl-4-pyridinone) Clin Chem 38 1992 562 565
42. G.J. Kontoghiorghes M.A. Aldouri A.V. Hoffbrand Effective chelation of iron in β-thalassemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one BMJ 295 1987 1509 1512
43. G.J. Kontoghiorghes M.A. Aldouri L.N. Sheppard 1,2-dimethyl-3-hydroxypyrid-4-one, an orally active chelator for the treatment of transfusional iron overload Lancet 1 1987 1294 1295
44. 1). I. Iron chelation and metabolic studies Br J Haematol 76 1990 295 300
45. G.J. Kontoghiorghes G. Goddard A.N. Bartlett Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one Clin Pharmacol Ther 48 1990 255 261
46. T.L. Litovitz K.C. Holm C. Clancy 1992 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System Am J Emerg Med 11 1993 494 555
47. G.F. Mabeza G. Biemba V.R. Gordeuk Clinical studies of iron chelators in malaria Acta Haematol 95 1996 78 86
48. J.R. Mahoney P.E. Hallaway B.E. Hedland Acute iron poisoning: Rescue with macromolecular chelators J Clin Invest 84 1989 1362 1366
49. J.J.M. Marx B.S. Van-Asbeck Use of iron chelators in preventing hydroxyl radical damage: Adult respiratory distress syndrome as a model for the pathophysiology and treatment of free radical–mediated tissue damage Acta Haematol 95 1996 49 62
50. D. Matsui J. Klein C. Hermann Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia Clin Pharmacol Ther 50 1991 294 298
51. J.T. McEnery J. Greengard Treatment of acute iron ingestion with deferoxamine in 20 children J Pediatr 68 1966 773 779
52. H.G. Meyer-Brunot H. Keberle The metabolism of desferrioxamine B Biochem Pharmacol 16 1967 527 537
53. 1 induces its metabolism in vitro in human hepatocyte lines. Proceedings of the Sixteenth World Congress of Anatomic and Clinical Pathology, Vancouver, 1991, p 15.
54. 1 Blood 84 suppl 1994 109
55. N.F. Olivieri G.M. Brittenham D. Matsui Iron chelation therapy with oral deferiprone in patients with thalassemia major N Engl J Med 14 1995 918 922
56. N.F. Olivieri J.R. Buncic E. Chew Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions N Engl J Med 314 1986 869 873
57. N.F. Olivieri J. Harris G. Koren Growth failure and bony changes induced by deferoxamine Am J Pediatr Hematol Oncol 14 1992 48 56
58. 1 and desferrioxamine in iron-loaded patients Lancet 336 1990 1275 1279
59. 1) in thalassemia major: One-year comparison with subcutaneous desferrioxamine Blood 78 suppl 1991 369
60. 1 in thalassemia intermedia Blood 79 1992 2741 2748
61. N.F. Olivieri D. Matsui M. Berkovitch Superior effectiveness of the oral chelator versus subcutaneous desferrioxamine in patients with homozygous beta-thalassemia (HBT): The impact of patient compliance during 2 years of therapy Blood 80 suppl 1992 344
62. N.F. Olivieri D.G. Nathan J.H. MacMillan Survival in medically treated patients with homozygous β-thalassemia N Engl J Med 331 1994 574 578
63. 1 Blood 84 suppl 1994 363
64. G. Peters H. Keberle K. Schmid Distribution and renal excretion of desferrioxamine and ferrioxamine in the dog and in the rat Biochem Pharmacol 15 1966 93 109
65. R.J. Polson A.S.M. Jawad A. Bomford Treatment of rheumatoid arthritis with desferrioxamine QJM 61 1986 1153 1158
66. J.B. Porter Evaluation of new iron chelators for clinical use Acta Haematol 95 1996 13 25
67. J.B. Porter E.R. Huehns The toxic effects of desferrioxamine Clin Haematol 2 1989 459 474
68. J.B. Porter E.R. Huens R. Hider The development of iron chelating drugs Baillieres Clin Haematol 2 1989 257 292
69. R.D. Propper B. Cooper R. Rufo Continuous subcutaneous administration of desferrioxamine in patients with iron overload N Engl J Med 297 1977 418 423
70. A.T. Proudfoot D. Simpson E.H. Dyson Management of acute iron poisoning Med Toxicol 1 1986 83 100
71. E. Rocchi P. Gilbertini M. Cassanelli Iron removal therapy in porphyria cutanea tarda: Phlebotomy versus slow subcutaneous desferrioxamine infusion Br J Dermatol 114 1986 621 629
72. 1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo Blood 86 1995 2008 2013
73. 1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassemia major Br J Haematol 76 1990 550 553
74. W.F. Weslin Deferoxamine in the treatment of acute iron poisoning. Clinical experience with 172 children Clin Pediatr 5 1966 531 535
75. F. Wohler The treatment of haemochromatosis with desferrioxamine Acta Haematol 30 1963 65 87
76. D.J. Wyler Bark, weeds, and iron chelators—drugs for malaria N Engl J Med 327 1992 1519 1521